SurgiVance
Private Company
Funding information not available
Overview
SurgiVance is pioneering a direct-to-digital pathology platform designed to transform surgical and diagnostic oncology workflows. Its integrated system, featuring a point-of-care tabletop imager, AI software, and proprietary disposables, generates pathology-grade digital images in under 60 seconds without calibration. The company targets critical applications in surgical margin screening, primary diagnosis, and clinical research, positioning itself at the foundation of future AI-enhanced diagnostic ecosystems. Backed by notable industry advisors, SurgiVance is addressing the slow, analog bottlenecks in traditional pathology.
Technology Platform
Direct-to-Digital Pathology Platform integrating a point-of-care tabletop imager with sub-cellular resolution (<1.0 µm), AI-powered image processing software, and proprietary disposable tissue specimen cassettes to generate digital pathology images in under 60 seconds without calibration.
Opportunities
Risk Factors
Competitive Landscape
SurgiVance competes with traditional digital pathology scanner companies (e.g., Roche, Philips) that digitize glass slides, but its direct-from-tester approach is disruptive. It also faces potential competition from other startups developing rapid optical biopsy technologies. Its key differentiator is the integrated, fast, point-of-care system designed for the surgical workflow.